Literature DB >> 17094386

Influence of transcatheter arterial chemoembolization on the prognosis after hepatectomy for hepatocellular carcinoma in patients with severe liver dysfunction.

Masaki Kaibori1, Noboru Tanigawa, Yoichi Matsui, Takamichi Saito, Yoichiro Uchida, Morihiko Ishizaki, Hironori Tanaka, Yasuo Kamiyama.   

Abstract

BACKGROUND: The influence of preoperative transcatheter arterial chemoembolization (TACE) on postoperative survival and recurrence of hepatocellular carcinoma (HCC) after resection is still controversial. The effect of preoperative TACE on the prognosis of HCC after hepatectomy in 243 patients with liver dysfunction was evaluated.
MATERIALS AND METHODS: Among 243 patients who underwent curative resection of HCC between 1992 and 2005, 124 patients had an indocyanine-green retention rate at 15 min (ICGR15) of <17% (49 underwent TACE), while 119 patients had an ICGR15 of > or =17% (66 underwent TACE). The clinical characteristics, operative results and long-term survival were compared between patients with and without preoperative TACE who had mild or severe liver dysfunction.
RESULTS: There was no significant difference in the recurrence-free and overall survival rates between the TACE and no TACE groups with an ICGR15 <17%. Among the 119 patients with an ICGR15 > or =17%, there were no significant differences of preoperative characteristics, operative findings, or histology between the two groups. However, the post-resection disease-free and overall survival rates of 66 patients who underwent TACE were significantly better than those of 53 patients who did not have TACE (p = 0.009 and p = 0.0099, respectively). Using multivariate analysis, preoperative TACE was independently associated with better disease-free and overall survival after resection in patients with an ICGR15 > or =17% (p = 0.0309 and p = 0.0162, respectively).
CONCLUSION: Preoperative TACE did not alter the prognosis after resection of HCC in patients with mild liver dysfunction, but it did improve the prognosis of patients with severe liver dysfunction.

Entities:  

Mesh:

Year:  2006        PMID: 17094386

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Preresection transarterial chemoembolization for hepatocellular carcinoma: an experience with 23 patients.

Authors:  Mahesh Goel; Vinay Gaikwad; Tejas Dharia; Suyash Kulkarni; Nitin Shetty; Shailesh V Shrikhande
Journal:  Indian J Gastroenterol       Date:  2014-07-19

2.  Liver resection for HCC outside the BCLC criteria.

Authors:  Manish S Bhandare; Shraddha Patkar; Nitin Shetty; Ashwin Polnaya; Suyash Kulkarni; Rohit R Dusane; Shailesh V Shrikhande; Mahesh Goel
Journal:  Langenbecks Arch Surg       Date:  2017-12-04       Impact factor: 3.445

3.  Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection.

Authors:  Yoji Kishi; Kiyoshi Hasegawa; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Int J Hepatol       Date:  2011-06-23

Review 4.  Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Xingshun Qi; Lei Liu; Diya Wang; Hongyu Li; Chunping Su; Xiaozhong Guo
Journal:  Oncotarget       Date:  2015-11-03

5.  Resection versus Resection with Preoperative Transcatheter Arterial Chemoembolization for Resectable Hepatocellular Carcinoma Recurrence.

Authors:  Qiang Tao; Wei He; Binkui Li; Yun Zheng; Ruhai Zou; Jingxian Shen; Wenwu Liu; Yuanping Zhang; Yunfei Yuan
Journal:  J Cancer       Date:  2018-07-16       Impact factor: 4.207

6.  Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma.

Authors:  Yanming Zhou; Xiaofeng Zhang; Lupeng Wu; Feng Ye; Xu Su; Lehua Shi; Bin Li
Journal:  BMC Gastroenterol       Date:  2013-03-19       Impact factor: 3.067

7.  Hepatic resection provided long-term survival for patients with intermediate and advanced-stage resectable hepatocellular carcinoma.

Authors:  Wei Liu; Kun Wang; Quan Bao; Yi Sun; Bao-Cai Xing
Journal:  World J Surg Oncol       Date:  2016-03-02       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.